Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has been given an average recommendation of “Hold” by the eight research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $23.54.

MNTA has been the topic of several research reports. Zacks Investment Research lowered shares of Farmers & Merchants Bancorp, Inc. (OH) from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 9th. BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $25.00 price objective on shares of Menlo Therapeutics in a research note on Thursday, May 2nd.

In other Momenta Pharmaceuticals news, insider Anthony M. Manning sold 39,433 shares of the business’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $13.00, for a total value of $512,629.00. Following the completion of the sale, the insider now directly owns 6,980 shares of the company’s stock, valued at $90,740. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Craig A. Wheeler sold 2,778 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $13.72, for a total transaction of $38,114.16. Following the completion of the sale, the chief executive officer now directly owns 23,330 shares of the company’s stock, valued at $320,087.60. The disclosure for this sale can be found here. Insiders sold 63,784 shares of company stock valued at $868,941 over the last three months. Insiders own 3.40% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Comerica Bank grew its holdings in shares of Momenta Pharmaceuticals by 20.7% during the fourth quarter. Comerica Bank now owns 91,808 shares of the biotechnology company’s stock worth $1,046,000 after purchasing an additional 15,776 shares during the last quarter. Prudential Financial Inc. increased its stake in shares of Momenta Pharmaceuticals by 17.9% during the 4th quarter. Prudential Financial Inc. now owns 152,792 shares of the biotechnology company’s stock worth $1,687,000 after purchasing an additional 23,200 shares in the last quarter. California Public Employees Retirement System increased its stake in shares of Momenta Pharmaceuticals by 9.1% during the 4th quarter. California Public Employees Retirement System now owns 125,246 shares of the biotechnology company’s stock worth $1,383,000 after purchasing an additional 10,400 shares in the last quarter. BlackRock Inc. increased its stake in shares of Momenta Pharmaceuticals by 14.0% during the 4th quarter. BlackRock Inc. now owns 13,775,141 shares of the biotechnology company’s stock worth $152,079,000 after purchasing an additional 1,694,797 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Momenta Pharmaceuticals by 17.0% during the 4th quarter. Bank of New York Mellon Corp now owns 1,046,251 shares of the biotechnology company’s stock worth $11,551,000 after purchasing an additional 152,220 shares in the last quarter. 97.43% of the stock is owned by institutional investors.

Shares of MNTA traded down $0.58 during mid-day trading on Friday, reaching $9.69. The company had a trading volume of 25,996 shares, compared to its average volume of 530,079. The firm has a market capitalization of $1.05 billion, a PE ratio of -4.81 and a beta of 2.13. The company’s fifty day simple moving average is $11.95. Momenta Pharmaceuticals has a fifty-two week low of $9.55 and a fifty-two week high of $32.20.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($0.01). The company had revenue of $4.11 million during the quarter, compared to analyst estimates of $10.12 million. Momenta Pharmaceuticals had a negative net margin of 231.49% and a negative return on equity of 43.98%. The firm’s quarterly revenue was down 15.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.63) EPS. On average, equities research analysts expect that Momenta Pharmaceuticals will post -1.79 earnings per share for the current fiscal year.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Featured Story: What is a blue-chip stock?

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.